Skip to main navigation Skip to main content Skip to footer For Medicare For Providers For Brokers For Employers Español For Individuals & Families: For Individuals & Families Medical Dental Other Supplemental Explore coverage through work How to Buy Health Insurance Types of Dental Insurance Open Enrollment vs. Special Enrollment See all topics Shop for Medicare plans Member Guide Find a Doctor Log in to myCigna
Home Knowledge Center Wellness Library casirivimab

casirivimab

Pronunciation: KAS i RIV i mab

What is the most important information I should know about casirivimab?

What is the most important information I should know about casirivimab?

Due to the high frequency of the Omicron BA.2 sub-variant, this drug is not currently authorized in any US region; therefore, this drug may not be administered for treatment of COVID-19 under the EUA until further notice by the US FDA.

What is casirivimab?

What is casirivimab?

Due to the high frequency of the Omicron BA.2 sub-variant, this drug is not currently authorized in any US region; therefore, this drug may not be administered for treatment of COVID-19 under the EUA until further notice by the US FDA.

Casirivimab is an experimental medicine being studied for use in treating conditions caused by coronavirus. It is not yet known if casirivimab is safe and effective.

Casirivimab and imdevimab are also for use in people who have been exposed to COVID-19 and:

  • are not fully vaccinated against COVID-19; or
  • are vaccinated but may not have built up enough immunity (because they have certain diseases or use certain medicines), and have been or may be exposed to people who are infected with COVID-19.

Casirivimab and imdevimab are for use in adults and children at least 12 years old who weigh at least 88 pounds (40 kilograms).

The risk of COVID-19 symptoms becoming severe may be higher in people who:

  • are overweight;
  • have chronic kidney disease;
  • have diabetes;
  • have a weak immune system (caused by disease or by using certain medicine);
  • have sickle cell disease;
  • have a heart problem or high blood pressure;
  • have a neurodevelopmental disorder such as cerebral palsy;
  • have asthma or other chronic breathing disorder; or
  • have a tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19).

There also may be a higher risk of severe COVID-19 symptoms in pregnant women and in adults who are 65 and older.

Casirivimab and imdevimab are mixed together into a single solution called Regen-Cov.

Casirivimab and imdevimab are not approved to treat or prevent coronavirus or COVID-19. However, these medicines may help prevent the need for emergency medical care or admission to a hospital because of COVID-19. Regen-Cov is not authorized for use in people who are already in the hospital or receiving supplemental oxygen for COVID-19.

Casirivimab may also be used for purposes not listed in this medication guide.

What should I discuss with my healthcare provider before receiving casirivimab?

What should I discuss with my healthcare provider before receiving casirivimab?

Tell your doctor if you have ever had:

  • a COVID-19 vaccine;
  • a severe allergic reaction to a COVID-19 vaccine;
  • any serious or chronic illness;
  • any allergies; or
  • if you are pregnant or breastfeeding.

COVID-19 is more likely to cause serious illness or death in a pregnant woman. Not all risks are known yet, but being treated with casirivimab and imdevimab is likely to be less harmful than being infected with COVID-19 during pregnancy.

How is casirivimab given?

How is casirivimab given?

Casirivimab and imdevimab (Regen-Cov) must be given as a combination. Casirivimab should not be used alone.

Regen-Cov is injected under the skin or into a vein by a healthcare provider.

When injected into a vein, Regen-Cov is given slowly over 20 to 50 minutes or longer. When injected under the skin, Regen-Cov is given as 2 to 4 separate injections into different areas of your body.

You will be watched for a short time after injection, to make sure you do not have an allergic reaction.

Regen-Cov is usually given as only one dose as soon as possible after you are exposed to or test positive for COVID-19, or within 10 days after the start of symptoms. You may need additional monthly doses if you continue to be exposed to COVID-19.

Being treated with Regen-Cov will not make you less contagious to other people. Keep using infection control methods such as self-isolation, social distancing, hand-washing, using protective face covering, disinfecting surfaces you touch a lot, and not sharing personal items with others.

Regen-Cov also may not keep you from becoming infected with coronavirus again. Being treated with this drug combination could also affect your body's immune response to a coronavirus vaccine. Casirivimab and imdevimab are still being studied and all of their risks are not yet known.

What happens if I miss a dose?

What happens if I miss a dose?

Call your doctor for instructions if you are on a monthly dose schedule and you miss an appointment for your injection.

What happens if I overdose?

What happens if I overdose?

In a medical setting an overdose would be treated quickly.

What should I avoid after receiving casirivimab?

What should I avoid after receiving casirivimab?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

What are the possible side effects of casirivimab?

What are the possible side effects of casirivimab?

Get emergency medical help if you have signs of an allergic reaction: hives, itching; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection. Tell your medical caregivers right away if you have:

  • throat irritation, swelling in your face or throat;
  • dizziness, a light-headed feeling (like you might pass out);
  • chest pain, wheezing, shortness of breath;
  • fever, chills, sweating, nausea, flushing (sudden warmth, redness, or tingly feeling);
  • fast or slow heartbeats, headache, pounding in your neck or ears;
  • weakness, tiredness;
  • rash, itching; or
  • muscle pain.

Call your doctor if you have new or worsening symptoms after the infusion, such as fever, confusion, weakness, tiredness, trouble breathing, or fast or slow heartbeats.

Less serious side effects may also occur, or you may have none at all. Not all possible side effects are known.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect casirivimab?

What other drugs will affect casirivimab?

Other drugs may affect casirivimab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Where can I get more information?

Where can I get more information?

Your doctor or pharmacist can provide more information about casirivimab.

This information does not replace the advice of a doctor. Healthwise, Incorporated, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Learn how we develop our content.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.

<cipublic-spinner variant="large"><span>Loading…</span></cipublic-spinner>

Page Footer

I want to...

Get an ID card File a claim View my claims and EOBs Check coverage under my plan See prescription drug list Find an in-network doctor, dentist, or facility Find a form Find 1095-B tax form information View the Cigna Glossary Contact Cigna

Audiences

Individuals and Families Medicare Employers Brokers Providers

Secure Member Sites

myCigna member portal Health Care Provider portal Cigna for Employers Client Resource Portal Cigna for Brokers

The Cigna Group Information

About The Cigna Group Company Profile Careers Newsroom Investors Suppliers The Cigna Group Third Party Administrators International Evernorth

 Cigna. All rights reserved.

Privacy Legal Product Disclosures Cigna Company Names Customer Rights Accessibility Non-Discrimination Notice Language Assistance [PDF] Report Fraud Sitemap Cookie Settings

Disclaimer

Individual and family medical and dental insurance plans are insured by Cigna Health and Life Insurance Company (CHLIC), Cigna HealthCare of Arizona, Inc., Cigna HealthCare of Illinois, Inc., Cigna HealthCare of Georgia, Inc., Cigna HealthCare of North Carolina, Inc., Cigna HealthCare of South Carolina, Inc., and Cigna HealthCare of Texas, Inc. Group health insurance and health benefit plans are insured or administered by CHLIC, Connecticut General Life Insurance Company (CGLIC), or their affiliates (see a listing of the legal entities that insure or administer group HMO, dental HMO, and other products or services in your state). Accidental Injury, Critical Illness, and Hospital Care plans or insurance policies are distributed exclusively by or through operating subsidiaries of Cigna Corporation, are administered by Cigna Health and Life Insurance Company, and are insured by either (i) Cigna Health and Life Insurance Company (Bloomfield, CT); (ii) Life Insurance Company of North America (“LINA”) (Philadelphia, PA); or (iii) New York Life Group Insurance Company of NY (“NYLGICNY”) (New York, NY), formerly known as Cigna Life Insurance Company of New York. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. LINA and NYLGICNY are not affiliates of Cigna.

All insurance policies and group benefit plans contain exclusions and limitations. For availability, costs and complete details of coverage, contact a licensed agent or Cigna sales representative. This website is not intended for residents of New Mexico.

Selecting these links will take you away from Cigna.com to another website, which may be a non-Cigna website. Cigna may not control the content or links of non-Cigna websites. Details